MX362375B - Extracto de saliva entera de sanguijuela. - Google Patents

Extracto de saliva entera de sanguijuela.

Info

Publication number
MX362375B
MX362375B MX2015003352A MX2015003352A MX362375B MX 362375 B MX362375 B MX 362375B MX 2015003352 A MX2015003352 A MX 2015003352A MX 2015003352 A MX2015003352 A MX 2015003352A MX 362375 B MX362375 B MX 362375B
Authority
MX
Mexico
Prior art keywords
leech
whole
saliva
extract
unrefined
Prior art date
Application number
MX2015003352A
Other languages
English (en)
Other versions
MX2015003352A (es
Inventor
Ahmed Merzouk
Abbas Mohammad Ghawi
Abdualrahman M Abdualkader
Mohamed Alaama
Original Assignee
Biopep Solutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopep Solutions Inc filed Critical Biopep Solutions Inc
Publication of MX2015003352A publication Critical patent/MX2015003352A/es
Publication of MX362375B publication Critical patent/MX362375B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/30—Rearing or breeding invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Hematology (AREA)
  • Animal Husbandry (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agronomy & Crop Science (AREA)
  • Biotechnology (AREA)

Abstract

La presente invención se refiere a el uso de una cantidad eficaz de un extracto de saliva entera de una sanguijuela en la fabricación de un medicamento para el tratamiento de hipoglucemia diabética, en donde el extracto se obtiene al: alimentar con un agente fagoestimulador a la sanguijuela; inducir una regurgitación en la sanguijuela en un medio que tiene una temperatura de menos de 0°C; recolectar una saliva entera no refinada en la regurgitación de la sanguijuela fría; separar componentes sólidos de la saliva entera no refinada para crear, una saliva entera refinada; y, liofilizar el extracto de saliva entera.
MX2015003352A 2012-09-17 2013-09-17 Extracto de saliva entera de sanguijuela. MX362375B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261701735P 2012-09-17 2012-09-17
US13/624,847 US8685462B1 (en) 2012-09-17 2012-09-21 Whole, leech saliva product and applications thereof
PCT/IB2013/002848 WO2014049447A2 (en) 2012-09-17 2013-09-17 A whole, leech saliva extract

Publications (2)

Publication Number Publication Date
MX2015003352A MX2015003352A (es) 2015-10-22
MX362375B true MX362375B (es) 2019-01-14

Family

ID=48876315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015003352A MX362375B (es) 2012-09-17 2013-09-17 Extracto de saliva entera de sanguijuela.

Country Status (10)

Country Link
US (17) US8685462B1 (es)
EP (1) EP2895178B1 (es)
JP (1) JP6220398B2 (es)
CN (1) CN104837495A (es)
AU (1) AU2013322269B2 (es)
CA (1) CA2882533A1 (es)
ES (1) ES2710126T3 (es)
IN (1) IN2015DN02729A (es)
MX (1) MX362375B (es)
WO (1) WO2014049447A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8685462B1 (en) 2012-09-17 2014-04-01 Biopep Solutions, Inc. Whole, leech saliva product and applications thereof
KR101341289B1 (ko) * 2013-07-09 2013-12-12 한선대 거머리 타액의 채취방법
CN104151425B (zh) * 2014-08-15 2017-02-08 周维海 一种天然水蛭素的规模化生产方法
CN104365560A (zh) * 2014-10-29 2015-02-25 颍上县永祥旱粮研究所 一种水蛭的养殖方法
CN105418756B (zh) * 2015-12-25 2018-12-21 汤浩强 一种水蛭唾液重复提取的方法
CN105594666B (zh) * 2015-12-25 2020-04-03 贵州信邦制药股份有限公司 一种快速增加水蛭抗凝血酶活性的养殖方法
CN108210523A (zh) * 2016-12-09 2018-06-29 江苏小潘园生态农业科技发展有限公司 一种水蛭酒的制作方法
CN107129962B (zh) * 2017-05-18 2019-03-05 中国计量大学 一种日本医蛭唾液腺细胞的原代培养方法
CN107519036A (zh) * 2017-09-06 2017-12-29 深圳肽之妃科技有限公司 一种含多肽的妊娠纹喷剂及其制备方法
CN107796183A (zh) * 2017-11-17 2018-03-13 广西远程水蛭养殖有限公司 水蛭干燥方法
CN109528773A (zh) * 2019-01-15 2019-03-29 昆明学院 水蛭唾液在制备镇痛药物中的应用
CN109662984B (zh) * 2019-02-13 2022-07-26 昆明医科大学 臭灵丹和迷迭香提取物在抗ⅱ型登革病毒药物中的应用
US10787338B1 (en) 2019-08-30 2020-09-29 Blazing Spools LLC Spool device and related methods
EP4208157A1 (en) 2020-09-04 2023-07-12 Elanco Us Inc. Palatable formulations
CN112915106A (zh) * 2021-02-05 2021-06-08 张虎山 一种肿瘤免疫微环境调控剂的制备及其应用
CN113577821B (zh) * 2021-07-07 2022-08-30 三峡大学 一种活体水蛭素的重复提取装置及方法
CN115671139A (zh) * 2022-11-07 2023-02-03 云南民族大学 水蛭提取物在银屑病外用药物研制中的应用
CN118005739B (zh) * 2024-04-09 2024-06-21 南京华盖制药有限公司 一种抗耐药菌株的多肽aph229及其制备方法和应用
CN118452369A (zh) * 2024-04-30 2024-08-09 云南云蛭康生物科技有限公司 一种菲牛蛭唾液提取诱导液配置方法
CN118406137B (zh) * 2024-07-01 2024-09-06 云南云蛭康生物科技有限公司 一种用于采集水蛭唾液提取物的装置

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588587A (en) 1983-03-01 1986-05-13 Pennsylvania Hospital Method of treatment to inhibit metastasis
JP2566934B2 (ja) 1985-08-10 1996-12-25 バイオフア−ム（ユ−ケイ）リミテツド 血小板凝集抑制作用を有するコラ−ゲン特異性酵素
US4832849A (en) 1988-06-16 1989-05-23 Merrell Dow Pharmaceuticals Inc. Extraction and purification of an anticoagulant principle from the south american leech, haementeria ghilianii
IL86857A (en) * 1988-06-24 1994-04-12 Yissum Res Dev Co Platelet-aggregating inhibitory agents from leech saliva and pharmaceutical preparations containing the same
GB8826428D0 (en) * 1988-11-11 1988-12-14 Biopharm Ltd Antithrombin
KR0185973B1 (ko) 1989-06-20 1999-05-01 게리 디. 스트리트 남미의 거머리인 헤멘테리아 길리아니로부터의 항전이 물질 길란텐
ZA904622B (en) 1989-06-20 1991-03-27 Merrell Dow Pharma Ghilanten:antimetastatic principle from the south american leech,haementeria ghilanii
DE4103649A1 (de) 1991-02-07 1992-08-13 Basf Ag Neue antikoagulatorisch wirksame peptide
AU659432B2 (en) 1991-03-08 1995-05-18 Novartis Ag A method for the inhibition or prevention of tumor cell metastasis with hirudin
DE4209110A1 (de) 1991-11-26 1993-05-27 Basf Ag Neue thrombininhibitorische proteine aus landblutegeln
DE4234921A1 (de) 1992-10-16 1994-04-21 Basf Ag Neues, die Gerinnungszeit des Blutes verlängerndes Protein aus dem Landblutegel Haemadipsa sylestris
AU682361B2 (en) 1993-04-09 1997-10-02 Bio-Technology General Corporation Novel polypeptide having factor XA inhibitory activity
GB9309509D0 (en) 1993-05-07 1993-06-23 Merck Patent Gmbh Thrombin inhibitors
WO1995004750A1 (en) 1993-08-09 1995-02-16 Athena Neurosciences, Inc. Tick derived protease inhibitor
ES2246498T3 (es) * 1995-11-13 2006-02-16 Vitaleech Bioscience N.V. Aislados antivirales obtenidos de sanguijuelas.
US5866120A (en) 1995-11-22 1999-02-02 Advanced Corneal Systems, Inc. Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase
US6610292B2 (en) 1995-11-22 2003-08-26 Ista Pharmaceuticals, Inc. Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders
EP0875564A1 (en) 1997-05-02 1998-11-04 Gerard Voerman Biologically active extract from the leech 'Limnatis nilotica'
SE512633C2 (sv) 1997-07-09 2000-04-17 Cecilia Johnsson Användning av hyaluronidas för reduktion av inflammatoriska cellinfiltrat
KR20020011138A (ko) 1999-06-12 2002-02-07 플레믹 크리스티안 히루디나리아 마닐렌시스 유래의 히알루로니다아제, 분리,정제 및 재조합적 제조 방법
KR20040049830A (ko) * 2001-07-09 2004-06-12 애프톤 코포레이션 간, 폐 및 식도의 암 및 전암 상태의 치료 및 예방
CN1273012C (zh) * 2003-01-15 2006-09-06 周维海 从菲牛蛭活体中提取天然水蛭素的方法
CN101230086A (zh) * 2007-01-22 2008-07-30 广东海洋大学 一种以菲牛蛭唾液为原材料的水蛭素生产工艺
WO2009018640A1 (en) 2007-08-07 2009-02-12 Universidade Federal De São Paulo Unifesp Use of platelet aggregation and coagulation inhibitors isolated from bauhinia sp.
US20110070184A1 (en) 2008-03-24 2011-03-24 Carolus Therpeutics, Inc. Methods and compositions for treating atherosclerosis and related condidtions
EP2316465A1 (en) 2009-10-15 2011-05-04 Centre National De La Recherche Scientifique Use of extract of leeches' saliva as anti-bacterial agent for the manufacture of different compositons
CN102258771A (zh) 2011-07-13 2011-11-30 中国药科大学 重组水蛭素在防治糖尿病性白内障中的应用
US8685462B1 (en) 2012-09-17 2014-04-01 Biopep Solutions, Inc. Whole, leech saliva product and applications thereof
CN102964446B (zh) * 2012-11-28 2014-08-13 周维官 一种吸血水蛭活体多次提取天然水蛭素方法

Also Published As

Publication number Publication date
US20160331790A1 (en) 2016-11-17
US20140079800A1 (en) 2014-03-20
US20150182562A1 (en) 2015-07-02
EP2895178A2 (en) 2015-07-22
US9433648B2 (en) 2016-09-06
WO2014049447A3 (en) 2014-06-19
US20150196607A1 (en) 2015-07-16
EP2895178B1 (en) 2018-11-07
US9597361B2 (en) 2017-03-21
JP6220398B2 (ja) 2017-10-25
AU2013322269B2 (en) 2018-05-31
US20150086645A1 (en) 2015-03-26
US20140363518A1 (en) 2014-12-11
US8790711B2 (en) 2014-07-29
US9144587B2 (en) 2015-09-29
CA2882533A1 (en) 2014-04-03
US9265802B2 (en) 2016-02-23
US20140079798A1 (en) 2014-03-20
US9149498B2 (en) 2015-10-06
US8784896B2 (en) 2014-07-22
CN104837495A (zh) 2015-08-12
US9017732B1 (en) 2015-04-28
MX2015003352A (es) 2015-10-22
US8685462B1 (en) 2014-04-01
US20160331789A1 (en) 2016-11-17
EP2895178A4 (en) 2016-05-25
US8932642B2 (en) 2015-01-13
US20160120914A1 (en) 2016-05-05
US10064897B2 (en) 2018-09-04
US9480720B1 (en) 2016-11-01
US20140356448A1 (en) 2014-12-04
US9265803B2 (en) 2016-02-23
AU2013322269A1 (en) 2015-03-05
US9433649B2 (en) 2016-09-06
US8962034B2 (en) 2015-02-24
JP2015528491A (ja) 2015-09-28
US8501241B1 (en) 2013-08-06
WO2014049447A2 (en) 2014-04-03
US20150099006A1 (en) 2015-04-09
IN2015DN02729A (es) 2015-09-04
US20160120913A1 (en) 2016-05-05
ES2710126T3 (es) 2019-04-23
US20170239301A1 (en) 2017-08-24
US20140079799A1 (en) 2014-03-20
US20150359826A1 (en) 2015-12-17
US20150359825A1 (en) 2015-12-17
US9005667B1 (en) 2015-04-14

Similar Documents

Publication Publication Date Title
MX362375B (es) Extracto de saliva entera de sanguijuela.
CL2019003800A1 (es) Métodos para tratar la enfermedad de huntington.
SV2010003673A (es) Compuestos heterociclicos novedosos y usos de los mismos
MX2013010343A (es) Composicion y metodos para el transplante de microbiota de colon.
ECSP13012661A (es) Composición farmacéutica, métodos de tratamiento y usos de la misma.
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
MX2016002077A (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
CL2012000620A1 (es) Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
BR112012030699A2 (pt) métodos para tratar câncer de bexiga
UA117098C2 (uk) Сполука, що містить модифікований олігонуклеотид
BR112012027747A2 (pt) método e composição imunogênica para tratamento de neoplásia
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
UY33397A (es) Forma sólida de un naftaleno carboxamida
MX341684B (es) Composicion para el uso en la prevencion y/o tratamiento de condiciones de la piel y enfermedades de la piel.
CR11723A (es) Agente para tratar enfermedad
TR201901110T4 (tr) Empagliflozinin terapötik kullanımları.
BR112012023660A2 (pt) novos métodos para direcionar células-tronco cancerosas
DOP2016000253A (es) Nuevos compuestos
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
BR112012026707A2 (pt) uso de um anticorpo anti-cd20 afucosilado, composição que compreende um anticorpo anti-cd20 afucosilado e método de tratamento de pacientes que sofrem de câncer por meio da administração de um anticorpo anti-cd20 afucosilado
ES2445846R1 (es) Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos
CL2014000050A1 (es) Composicion farmaceutica en forma de solucion que comprende apomorfina, un codisolvente micible en agua, un antioxidante y agua, en la que el ph es superior a 4; procedimiento para fabricarla; y su uso como solucion inyectable en el tratamiento de la enfermedad de parkinson.
MX2013011124A (es) Compuestos para el tratamiento del sindrome metabolico.
MX381102B (es) Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2

Legal Events

Date Code Title Description
FG Grant or registration